The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2015

Filed:

Nov. 17, 2011
Applicants:

Kyung Seop Ahn, Daejeon, KR;

Ha Young Jang, Daejeon, KR;

Sei Ryang OH, Daejeon, KR;

Hyeong Kyu Lee, Daejeon, KR;

Ok-kyoung Kwon, Daejeon, KR;

Semi Kim, Daejeon, KR;

Jung Hee Kim, Daejeon, KR;

Doo-young Kim, Daejeon, KR;

Inventors:

Kyung Seop Ahn, Daejeon, KR;

Ha Young Jang, Daejeon, KR;

Sei Ryang Oh, Daejeon, KR;

Hyeong Kyu Lee, Daejeon, KR;

Ok-Kyoung Kwon, Daejeon, KR;

Semi Kim, Daejeon, KR;

Jung Hee Kim, Daejeon, KR;

Doo-Young Kim, Daejeon, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/70 (2006.01); A61K 31/34 (2006.01); A61K 31/7048 (2006.01); A61K 31/343 (2006.01); A61K 36/185 (2006.01); A23L 1/30 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7048 (2013.01); A61K 31/343 (2013.01); A61K 36/185 (2013.01); A23L 1/3002 (2013.01); A23V 2002/00 (2013.01);
Abstract

The present invention relates to a pharmaceutical composition for preventing or treating asthma, the composition containing styraxlignolide A or an aglycone thereof as an active ingredient. More particularly, styraxlignolide A compound is one separated from stems and barks of, and styraxlignolide A or homoegonol, which is an aglycone of styraxlignolide A and which has improved safety, has the effect of attenuating weight loss and airway hyperresponsiveness, inhibiting the generation of reactive oxygen species in airway, inhibiting generation of IgE, TGF-β1, and IL-17 in the serum and bronchoalveolar lavage fluid, inhibiting endobronchial inflammatory cell infiltration, and inhibiting the formation of a mucous plug and subepithelial fibrosis in an asthma-induced mouse model. Therefore, styraxlignolide or homoegonol can be effectively used as the active ingredient of a pharmaceutical composition for preventing or treating bronchial asthma in which airway remodeling has progressed.


Find Patent Forward Citations

Loading…